A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

NCT03764293 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

543

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic and Unresectable HCC

Interventions

DRUG: SHR-1210
DRUG: Apatinib
DRUG: Sorafenib

Sponsor

Jiangsu HengRui Medicine Co., Ltd.